Gene therapy for RPE65-mediated inherited retinal dystrophy completes phase 3

被引：7
|
作者：
Lee, Helena [1 ]
Lotery, Andrew [1 ]
机构：
[1] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO16 6YD, Hants, England
来源：
LANCET | 2017年 / 390卷 / 10097期
基金：
英国医学研究理事会;
关键词：
LEBERS CONGENITAL AMAUROSIS; ADENOASSOCIATED VIRUS; RPE65; MUTATIONS; SAFETY; TRIAL;
D O I：
10.1016/S0140-6736(17)31622-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：823 / 824
页数：2
相关论文
共 50 条
  • [31] Correlation of multi-luminance mobility testing with visual function tests in a phase 3 trial of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease
    Chung, Daniel C.
    Russell, Stephen R.
    Bennett, Jean
    Maguire, Albert M.
    Wellman, Jennifer A.
    Yu, Zi-Fan
    Tillman, Amy
    High, Katherine A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [32] Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease
    Johnson, Scott
    Buessing, Marric
    O'Connell, Thomas
    Pitluck, Sarah
    Ciulla, Thomas A.
    JAMA OPHTHALMOLOGY, 2019, 137 (10) : 1115 - 1123
  • [33] A COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE
    Zimmermann, M. R.
    Lubinga, S. J.
    Rind, D.
    Chapman, R. H.
    Carlson, J. J.
    VALUE IN HEALTH, 2018, 21 : S205 - S206
  • [34] COST-EFFECTIVENESS ANALYSIS OF VORETIGENE NEPARVOVEC VERSUS BEST SUPPORTIVE CARE IN PATIENTS WITH RPE65-MEDIATED INHERITED RETINAL DYSTROPHY: A FRENCH HEALTHCARE SYSTEM PERSPECTIVE
    Cariou, C.
    Baba, J.
    Gherardi, A.
    Roze, S.
    Viriato, D.
    VALUE IN HEALTH, 2019, 22 : S405 - S405
  • [35] Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa
    Kwak, Jay Jiyong
    Kim, Hae Rang
    Byeon, Suk Ho
    YONSEI MEDICAL JOURNAL, 2022, 63 (07) : 701 - 705
  • [36] Rpe65 as a modifier gene for inherited retinal degeneration
    Samardzija, M
    Wenzel, A
    Naash, M
    Remé, CE
    Grimm, C
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2006, 23 (04) : 1028 - 1034
  • [37] Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation
    Ameri, Hossein
    JOURNAL OF CURRENT OPHTHALMOLOGY, 2018, 30 (01): : 1 - 2
  • [38] COST-EFFECTIVENESS OF VORETIGENE NEPARVOVEC FOR VISION LOSS DUE TO BIALLELIC RPE65-MEDIATED INHERITED RETINAL DISEASE IN A DANISH SETTING
    Ploug, U.
    VALUE IN HEALTH, 2019, 22 : S846 - S846
  • [39] RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy
    Sodi, Andrea
    Banfi, Sandro
    Testa, Francesco
    Della Corte, Michele
    Passerini, Ilaria
    Pelo, Elisabetta
    Rossi, Settimio
    Simonelli, Francesca
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [40] RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy
    Andrea Sodi
    Sandro Banfi
    Francesco Testa
    Michele Della Corte
    Ilaria Passerini
    Elisabetta Pelo
    Settimio Rossi
    Francesca Simonelli
    Orphanet Journal of Rare Diseases, 16
12345